Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.

Cancers (Basel) · 2023 · PMC10486537 · PMID 37686606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

While there could be no or little difference in efficacy between the low- and full-dose regimen in young patients, there may be significant difference in elderly patients.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.